# EDGAR Filing Document

**Accession Number:** 0001842295
**File Stem:** 9999999995-26-001606
**Filing Date:** 2026-5
**Character Count:** 1366
**Document Hash:** 240cc29d0577fa6f4c08e95cc373b2cd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**9999999995-26-001606.hdr.sgml**: 20260514

**ACCESSION NUMBER**: 9999999995-26-001606

**CONFORMED SUBMISSION TYPE**: EFFECT

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260513

**DATE AS OF CHANGE**: 20260514

**EFFECTIVENESS DATE**: 20260513

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Maze Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001842295
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** EFFECT
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-290935
- **FILM NUMBER:** 26975612

**BUSINESS ADDRESS:**
- **STREET 1:** 171 OYSTER POINT BOULEVARD, SUITE 300
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 6508505070

**MAIL ADDRESS:**
- **STREET 1:** 171 OYSTER POINT BOULEVARD, SUITE 300
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

### UNITED STATES
### SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## Notice of Effectiveness

**Date:** May 13, 2026

**Accession Number:** 0001193125-26-219386

**Form Type:** POS AM

---

**CIK:** 0001842295

**Company Name:** Maze Therapeutics, Inc.

**File Number:** 333-290935